Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Non-Current Assets: 2020-2025

Historic Non-Current Assets for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $46.4 million.

  • Tango Therapeutics' Non-Current Assets fell 10.16% to $46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.4 million, marking a year-over-year decrease of 10.16%. This contributed to the annual value of $50.1 million for FY2024, which is 10.49% down from last year.
  • Per Tango Therapeutics' latest filing, its Non-Current Assets stood at $46.4 million for Q3 2025, which was down 3.00% from $47.8 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Non-Current Assets peaked at $166.8 million during Q2 2021, and registered a low of $7.8 million during Q4 2021.
  • For the 3-year period, Tango Therapeutics' Non-Current Assets averaged around $53.2 million, with its median value being $53.0 million (2024).
  • Data for Tango Therapeutics' Non-Current Assets shows a peak YoY increase of 682.88% (in 2022) and a maximum YoY decrease of 93.48% (in 2022) over the last 5 years.
  • Over the past 5 years, Tango Therapeutics' Non-Current Assets (Quarterly) stood at $7.8 million in 2021, then spiked by 682.88% to $61.2 million in 2022, then declined by 8.45% to $56.0 million in 2023, then fell by 10.49% to $50.1 million in 2024, then decreased by 10.16% to $46.4 million in 2025.
  • Its last three reported values are $46.4 million in Q3 2025, $47.8 million for Q2 2025, and $49.4 million during Q1 2025.